Takeda allies with Resolve to develop autoimmune disease drugs

03/1/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical and Resolve Therapeutics agreed to collaborate on treatments for systemic lupus erythematosus and other autoimmune disorders, with an initial focus on Resolve's nuclease Fc fusion protein RSLV-132. The deal gives Takeda an exclusive option to license all Resolve compounds following a study on RSLV-132. Resolve will get $8 million for clinical development, a potential option exercise payment and as much as $247 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI